Skip to content
ApprovedFDA approved

Dutasteride (Avodart)

Prescription prostate medicine, also used off-label for hair loss. It lowers levels of the hormone DHT by about 90–95%.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Dutasteride (Avodart) vial

Related comparisons

Finasteride vs Dutasteride

DETAILED OVERVIEW

What is Dutasteride (Avodart)?

Dutasteride (Avodart) is a prescription medicine approved for an enlarged prostate. For hair loss it is used only off-label in the USA and the EU; steroid-using bodybuilders also use it against the hair loss and acne that appear alongside steroids.

It blocks both types of the enzyme that turns testosterone into DHT (dihydrotestosterone, a strong male hormone), lowering DHT by about 90–95%. It leaves the body very slowly, with full clearance taking about six months, which also affects family planning. Reduced sex drive, erection and ejaculation problems and depression can occur; these can be more frequent and longer lasting than with finasteride, and they can persist after stopping. It must not be used in pregnancy, because it can harm the development of a male baby's genitals, and a pregnant woman must not touch the contents of a leaking capsule. It is not on the anti-doping list.

Mechanism

Blocks both types of the DHT-forming enzyme; about 90% less DHT in the scalp

Half-life

~5 weeks (very long, steady-state ~6 months, washout ~6 months)

Onset

DHT reduction measurable 1 week, hair stabilization 3-6 months

Legal status

FDA + EMA Rx (BPH), HU + PL approved, off-label AGA US/EU, WADA allowed

Data console

Lab data

Androgenic:AnabolicN/A (not AAS, dual-5AR inhibitor)
AR bindingType-I 5AR Ki ~6 nM, Type-II 5AR Ki ~7 nM. Finasteride…
Active half-life~5 weeks (parent compound active), washout ~6 months full elimination
Detection windowRemoved from WADA list 2009 (5AR masking agent) – competition-context allowed.
AromatizationDoes not aromatize – competitive dual 5AR inhibitor; blocks DHT conversion (type-I + type-II), no effect on aromatase.
HepatotoxicityLow; steroid-like structure BUT NOT 17α-alkylated. Hepatic AE <2% (FDA Avodart label). PFS-like syndrome documented on dutasteride too (Trost 2017 PMID 28267184), more frequent than on finasteride due to stronger + longer effect.

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Sexual side effects: reduced libido, erectile dysfunction, decreased ejaculate volume, and less commonly orgasmic dysfunction (more frequent and more persistent than with finasteride).
  • Persistent post-5AR-inhibitor syndrome (PFS-like): sexual, neurological and mood symptoms that may persist after discontinuation; symptoms resolve more slowly than with finasteride due to the long half-life.
  • Mood disturbances: depression, anxiety and rarely suicidal ideation; history of depression increases the risk (documented by Trost 2017).
  • Gynecomastia and breast tenderness: breast swelling or tenderness due to the shifted DHT/estrogen ratio (uncommon, listed in the FDA label).
  • Reduced sperm count, motility and ejaculate volume with transient impaired fertility; due to the ~6-month washout, it must be stopped well ahead of planning conception.
  • Lowers serum PSA by roughly 50%, which can mask a prostate cancer screening signal; PSA results on a 5AR inhibitor must be interpreted as doubled.
  • Allergic reactions: rash, pruritus, urticaria, localized edema and rarely angioedema may occur.

Contraindications · 7

  • Pregnant or potentially pregnant women must not handle leaking/broken capsules or take it (Pregnancy Category X): DHT suppression disrupts male fetal genital development.
  • Active plans to conceive: due to the ~6-month washout it must be stopped well before conception; the drug is excreted into semen.
  • Hypersensitivity to dutasteride or other 5-alpha-reductase inhibitors.
  • Age under 18 and women (especially those of childbearing potential): not an indicated population.
  • Active depression or suicide risk, or a history of PFS-like symptoms: increased risk of mood and persistent side effects.
  • Severe hepatic impairment: metabolism is predominantly hepatic, caution is required (renal excretion is minimal).
  • Blood donation prohibition: must not donate blood during treatment and for at least 6 months after the last dose, to avoid exposure of a pregnant recipient.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Dutasteride (Avodart)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.